Table 1 Characteristics of all 16 patients investigated in this study
Patient | Age | Gender | Body mass (kg) | Initial stage | Number of regimen | Time between pre-therapeutic PET and Zevalin therapy (days) | Time between Zevalin therapy and post-therapeutic CT (days) | Number of lesions a | Response classification b |
|---|---|---|---|---|---|---|---|---|---|
1 | 49 | M | 93.4 | IIIb | 1 | 23 | 65 | 2 | CRu |
2 | 74 | M | 63.4 | IIIa | 2 | 4 | 63 | 2 | CR |
3 | 67 | F | 50.6 | II | 4 | 57 | 91 | 4 | PR |
4 | 61 | F | 54.6 | I | 1 | 50 | 78 | 1 | CR |
5 | 58 | M | 73.6 | I | 1 | 55 | 58 | 1 | CR |
6 | 72 | M | 66.4 | IV | 2 | 71 | 68 | 7 | CR |
7 | 71 | F | 57.7 | IV | 2 | 58 | 75 | 5 | CR |
8 | 73 | M | 63.4 | II | 3 | 14 | 64 | 4 | PD |
9 | 66 | M | 62.9 | IIIa | 3 | 33 | 62 | 6 | SD |
10 | 71 | M | 53.6 | I | 2 | 42 | 77 | 1 | SD |
11 | 68 | F | 49.1 | IV | 3 | 27 | 62 | 1 | CR |
12 | 79 | F | 43.0 | IV | 1 | 53 | 65 | 1 | SD |
13 | 61 | F | 60.7 | I | 2 | 41 | 92 | 1 | PD |
14 | 76 | M | 57.3 | III | 1 | 50 | 99 | 1 | CR |
15 | 65 | M | 50.7 | IV | 1 | 46 | 62 | 4 | CR |
16 | 66 | M | 49.0 | III | 1 | 15 | 75 | 1 | PR |